ERASCA INC. - COMMON

Erasca Reports Third Quarter 2024 Business Updates and Financial Results

12 Nov 2024 15:01:00 By Nasdaq GlobeNewswire

Erasca to Present at Upcoming Investor Conferences

05 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise

24 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium

25 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Erasca to Present at Upcoming Investor Conferences in September

29 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Erasca Reports Second Quarter 2024 Business Updates and Financial Results

12 Aug 2024 15:01:00 By Nasdaq GlobeNewswire

Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients with NRAS-Mutant Melanoma

18 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Erasca to Present at Upcoming Investor Conferences in June

29 May 2024 07:00:00 By Nasdaq GlobeNewswire

Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

21 May 2024 15:05:00 By Nasdaq GlobeNewswire

Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise

16 May 2024 19:02:00 By Nasdaq GlobeNewswire

Erasca Announces Pricing of Underwritten Offering of Common Stock

16 May 2024 19:00:00 By Nasdaq GlobeNewswire

Erasca Reports First Quarter 2024 Business Updates and Financial Results

08 May 2024 15:01:00 By Nasdaq GlobeNewswire

Erasca to Present at the Bank of America Health Care Conference

07 May 2024 07:00:01 By Nasdaq GlobeNewswire

Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting

24 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

Erasca Announces $45 Million Oversubscribed Private Placement Financing

27 Mar 2024 19:30:00 By Nasdaq GlobeNewswire

Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

27 Mar 2024 15:01:00 By Nasdaq GlobeNewswire

Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials

14 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

01 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma

11 Dec 2023 07:00:00 By Nasdaq GlobeNewswire